Gene Editing Pioneers Launch Beam Therapeutics With $87 Million Series A Round

Gene Editing Pioneers Launch Beam Therapeutics With $87 Million Series A Round

Source: 
CP Wire
snippet: 

Beam Therapeutics announced today that it is launching to develop precision genetic medicines that make edits to individual base pairs in the genetic code. Co-founded by scientific pioneers known for advancing CRISPR gene editing, Beam is the first company to pursue development of new therapies using CRISPR base editing technology.